# Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

> **NCT01502592** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Breast Cancer
- Invasive Adenocarcinoma of the Breast

## Interventions

- **PROCEDURE:** Cryoablation
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT01502592
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502592, "Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01502592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*